2022
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients
Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.Peer-Reviewed Original ResearchConceptsRECIST response rateProgression-free survivalMetastatic/recurrent diseaseOverall survivalInduction chemotherapyRecurrent diseaseNeck cancerMetastatic/recurrent headPFS/overall survivalMean progression-free survivalSuccessful induction rateMean overall survivalPercent of patientsCases of metastasisFrail subsetWeekly paclitaxelFrail patientsAdult patientsElderly patientsPerformance statusRecurrent headInduction cohortInduction groupPatientsRecurrent group
2009
Accelerated Hypofractionated Radiation vs. Standard Fractionated Radiation Concurrent with Cetuximab Chemotherapy in Locally Advanced Head and Neck Cancer (LAHNC)
Galper S, Deshpande H, Rose M, Colasanto J, Decker R. Accelerated Hypofractionated Radiation vs. Standard Fractionated Radiation Concurrent with Cetuximab Chemotherapy in Locally Advanced Head and Neck Cancer (LAHNC). International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s433-s434. DOI: 10.1016/j.ijrobp.2009.07.992.Peer-Reviewed Original ResearchCetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)
Galper S, Deshpande H, Rose M, Decker R. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). Journal Of Clinical Oncology 2009, 27: e17030-e17030. DOI: 10.1200/jco.2009.27.15_suppl.e17030.Peer-Reviewed Original ResearchOverall survivalCHRT groupLate toxicityMucosal toxicityAcute mucosal toxicityHigher daily doseTumor registry dataOverall treatment timeDefinitive chemoradiationAcute mucositisConcurrent chemoradiationAdvanced headCompliant patientsLess weight lossRandomized studySkin necrosisCisplatin chemoradiationDaily doseDistant metastasisPatient chartsNeck cancerAltered fractionationRadiation fractionationRegistry dataNonsignificant decrease